Cargando…
Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma
SIMPLE SUMMARY: Syndecans (SDCs; SDC1 to 4) are integral cell surface proteoglycans that are expressed normally on various types of mammalian tissues. In cancer, SDCs’ expression is dysregulated, impacting the onset and progression of cancer by modulating pivotal signaling pathways involved in biolo...
Autores principales: | Motta, Juliana Maria, Hassan, Hebatallah, Ibrahim, Sherif Abdelaziz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046401/ https://www.ncbi.nlm.nih.gov/pubmed/36980680 http://dx.doi.org/10.3390/cancers15061794 |
Ejemplares similares
-
Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes
por: Nassar, Eyyad, et al.
Publicado: (2021) -
The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4(+) T cell polarization in inflammatory and non-inflammatory breast cancer patients
por: Saleh, Moshira Ezzat, et al.
Publicado: (2019) -
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
por: Ibrahim, Sherif Abdelaziz, et al.
Publicado: (2017) -
Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas
por: Loussouarn, D, et al.
Publicado: (2008) -
Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 Signaling
por: Ibrahim, Sherif A., et al.
Publicado: (2013)